Cancer Stem Cells in Pheochromocytoma and Paraganglioma
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors associated with high cardiovascular morbidity and variable risk of malignancy. The current therapy of choice is surgical resection. Nevertheless, PCCs/PGLs are associated with a lifelong risk of tumor persistence or recurrence. A high rate of germline or somatic mutations in numerous genes has been found in these tumors. For some, the tumorigenic processes are initiated during embryogenesis. Such tumors carry gene mutations leading to pseudohypoxic phenotypes and show more immature characteristics than other chromaffin cell tumors; they are also often multifocal or metastatic and occur at an early age, often during childhood. Cancer stem cells (CSCs) are cells with an inherent ability of self-renewal, de-differentiation, and capacity to initiate and maintain malignant tumor growth. Targeting CSCs to inhibit cancer progression has become an attractive anti-cancer therapeutic strategy. Despite progress for this strategy for solid tumors such as neuroblastoma, brain, breast, and colon cancers, no substantial advance has been made employing similar strategies in PCCs/PGLs. In the current review, we discuss findings related to the identification of normal chromaffin stem cells and CSCs, pathways involved in regulating the development of CSCs, and the importance of the stem cell niche in development and maintenance of CSCs in PCCs/PGLs. Additionally, we examine the development and feasibility of novel CSC...
Foods high in soluble fiber like oatmeal, nuts and beans were associated with reduced breast cancer incidence.
Publication date: Available online 4 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Kaili Wang, Weijie Zhang, Zihan Wang, Ming Gao, Xinying Wang, Wenchao Han, Nan Zhang, Xia Xu
Publication date: Available online 5 April 2020Source: Seminars in Cancer BiologyAuthor(s): Emad A. Rakha, Fresia G. Pareja
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Michela Biancolella, Barbara Testa, Leila Baghernajad Salehi, Maria Rosaria D’Apice, Giuseppe Novelli
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Jyoti Gupta, Haaris Ahsan Safdari, Mehboob Hoque
CONCLUSION: Here, we present what, to the best of our knowledge, is the first reported case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab. PMID: 32245391 [PubMed - as supplied by publisher]
Publication date: Available online 4 April 2020Source: Stem Cell ResearchAuthor(s): Simone B. Larsen, Zoé Hanss, Gérald Cruciani, François Massart, Peter A. Barbuti, George Mellick, Rejko Krüger
British Journal of Cancer, Published online: 06 April 2020; doi:10.1038/s41416-020-0822-xCombining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
AbstractPurpose of ReviewDetection of BRCA germline mutations (gBRCAm) impacts breast cancer medical treatment —according to differential sensitivity to cytotoxic chemotherapy and the activity of PARP inhibitors—and not only familial prevention. Guidelines for genetic testing—initially mainly based on familial history, age, and triple negative breast cancer (TNBC) subtype—currently are expanding in o rder to offer new therapeutic options.Recent FindingsIn the early setting, gBRCAm patients present a similar outcome as the non-carrier population with standard neoadjuvant chemotherapy, and the role of...